Claims for Patent: 10,300,054

Summary for Patent: 10,300,054

Title:	Methods for treating antipsychotic-induced weight gain
Abstract:	The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
Inventor(s):	Deaver; Daniel (Franklin, MA), Todtenkopf; Mark (Franklin, MA)
Assignee:	Alkermes Pharma Ireland Limited (Dublin, IE)
Application Number:	15/923,084
Patent Claims:	1. A composition comprising olanzapine and a compound of formula ##STR00022## or a pharmaceutically acceptable salt thereof. 2. The composition of claim 1, wherein the composition comprises the pharmaceutically acceptable salt of the compound of formula ##STR00023## 3. The composition according to claim 1, wherein the composition is in the form of a tablet. 4. The composition according to claim 1, wherein the composition is adapted for oral administration. 5. The composition according to claim 1, wherein the composition comprises from about 3 to about 30 mg of a compound of formula ##STR00024## or a pharmaceutically acceptable salt thereof. 6. The composition according to claim 5, wherein the composition comprises from about 3 to about 15 mg of a compound of formula ##STR00025## or a pharmaceutically acceptable salt thereof. 7. The composition according to claim 6, wherein the composition comprises 10 mg of a compound of formula ##STR00026## or a pharmaceutically acceptable salt thereof. 8. A method of treating a disease or disorder selected from schizophrenia, bipolar disorder, acute mania, bipolar I disorders with a single manic episode, or bipolar I disorders manifesting a mixed most recent episode comprising administering a composition comprising olanzapine and a compound of formula ##STR00027## or a pharmaceutically acceptable salt thereof. 9. The method of claim 8, wherein the composition comprises the pharmaceutically acceptable salt of the compound of formula ##STR00028## 10. The method according to claim 8, wherein the composition is administered orally. 11. The method according to claim 8, wherein the composition is administered daily. 12. The method according to claim 8, wherein the composition is in the form of a tablet. 13. The method according to claim 8, wherein said compound of formula ##STR00029## or a pharmaceutically acceptable salt thereof is administered in a dose of about 3 to about 30 mg. 14. The method according to claim 13, wherein said compound of formula ##STR00030## or a pharmaceutically acceptable salt thereof is administered in a dose of about 3 to about 15 mg. 15. The method according to claim 14, wherein said compound of formula ##STR00031## or a pharmaceutically acceptable salt thereof is administered in a dose of 10 mg. 16. The method according to claim 8, wherein the disease or disorder is schizophrenia. 17. The method according to claim 8, wherein the disease or disorder is bipolar disorder. 18. The method according to claim 8, wherein the disease or disorder is acute mania. 19. The method according to claim 8, wherein the disease or disorder is bipolar I disorders with a single manic episode. 20. The method according to claim 8, wherein the disease or disorder is bipolar I disorders manifesting a mixed most recent episode.